Abstracts tagged "DMARDs"

Abstract Number: 2523 • 2018 ACR/ARHP Annual Meeting
Rapid Response with Upadacitinib Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Csdmards or Bdmards
Oliver FitzGerald¹, Andrea Rubbert-Roth², Kun Chen³, Sebastian Meerwein⁴, Jose Jeffrey Enejosa³, Tim Shaw³ and Alvin F. Wells⁵, ¹St. Vincent’s Univ Hospital and Conway Inst Univ College Dublin, Dublin, Ireland, ²Kantonsspital St. Gallen, St Gallen, Switzerland, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Deutschland, Ludwigshafen, Germany, ⁵Rheum and Immunotherapy Ctr, Franklin, WI
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients (pts) with moderate to severe rheumatoid arthritis (RA) with an inadequate…
Abstract Number: 544 • 2018 ACR/ARHP Annual Meeting
Does Anti-Citrullinated Protein Antibody Status Modify Treatment Effect of Certain Biologic DMARDs?
Evo Alemao¹, Yedid Elbez², Yogesh Saini³, Sean E. Connolly¹, Aarti Rao³, Christine K Iannaccone⁴, Michael E Weinblatt⁴ and Nancy A. Shadick⁴, ¹Bristol-Myers Squibb, Princeton, NJ, ²Excelya, Boulogne-Billancourt, France, ³Mu Sigma, Bangalore, India, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Multiple therapeutic options with different mechanistic actions are available to treat patients (pts) with RA. However, selecting therapies by the characteristics of pts with…
Abstract Number: 963 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program
Stanley Cohen¹, Yoshiya Tanaka², Xavier Mariette³, Jeffrey R. Curtis⁴, Eun Bong Lee⁵, Peter Nash⁶, Kevin Winthrop⁷, Christina Charles-Schoeman⁸, Lisy Wang⁹, Connie Chen¹⁰, Kenneth Kwok¹⁰, Pinaki Biswas¹⁰, Andrea Shapiro¹¹, Ann Madsen¹⁰ and Jürgen Wollenhaupt¹², ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Paris-Sud University, Le Kremlin Bicêtre, France, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Seoul National University, Seoul, Korea, Republic of (South), ⁶University of Queensland, Brisbane, Australia, ⁷Oregon Health and Science University, Portland, OR, ⁸University of California, Los Angeles, CA, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, New York, NY, ¹¹Pfizer Inc, Peapack, NJ, ¹²Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Here, we report the largest integrated safety analysis of tofacitinib to date…
Abstract Number: 1892 • 2018 ACR/ARHP Annual Meeting
Patient and Health System Characteristics Associated with Receipt of Disease Modifying Anti-Rheumatic Drugs in a National VA Sample
Jennifer Barton^1,2, Aldona Herrndorf³, Gabriela Schmajuk⁴, Rachel A. Matsumoto³, Linda Ganzini^2,3 and Kathleen Carlson^2,3, ¹Rheumatology, VA Portland Health Care System, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³VA Portland Health Care System, Portland, OR, ⁴San Francisco VA Medical Center, San Francisco, CA
Background/Purpose: The Department of Veterans Affairs (VA) operates the largest integrated health care system in the U.S. The proportion of Veterans with RA who receive…
Abstract Number: 2541 • 2018 ACR/ARHP Annual Meeting
Impact of 12-Weeks of Upadacitinib Treatment on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic or Biologic Dmards
Ronald van Vollenhoven¹, Robin K. Dore², Kun Chen³, Heidi S. Camp³, Jose Jeffrey Enejosa³, Tim Shaw³, Jessica Suboticki³ and Stephen Hall⁴, ¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²Univ of California, Los Angeles, CA, ³AbbVie Inc., North Chicago, IL, ⁴Department of Medicine, Monash University, Cabrini Health and Emeritus Research, Malvern, Australia
Background/Purpose: Upadacitinib (UPA), an oral, JAK1-selective inhibitor, demonstrated efficacy through 12 and 24 weeks (wks) in phase 3 trials of patients (pts) with active rheumatoid…
Abstract Number: 545 • 2018 ACR/ARHP Annual Meeting
How to Treat Rheumatoid Arthritis Patients When Methotrexate Has Failed? Results from the Meteor Registry
Sytske Anne Bergstra¹, Lai-Ling Winchow², Elizabeth Murphy³, Arvind Chopra⁴, Karen Salomon-Escoto⁵, João E. Fonseca⁶, Cornelia F. Allaart¹ and Robert B.M. Landewé⁷, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, ²University of the Witwatersrand, Johannesburg, South Africa, ³University Hospital Wishaw, Scotland, Wishaw, United Kingdom, ⁴Center for Rheumatic Diseases, Pune, India, ⁵University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, MA, ⁶Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ⁷Amsterdam Rheumatology & Immunology Center | Zuyderland Medical Center, Heerlen, Netherlands
Background/Purpose: After failure of initial methotrexate (MTX) treatment in rheumatoid arthritis (RA) patients, various treatment options can be considered. To date, evidence about the preferred…
Abstract Number: 1221 • 2018 ACR/ARHP Annual Meeting
Serologic Screening for Coccidioidomycosis Among Medicare Beneficiaries with Rheumatic Diseases on Biologic Response Modifiers, Corticosteroids, and Dmards
Shubha Kollampare¹, C. Kent Kwoh^1,2, Wei-Hsuan Lo-Ciganic³, Lili Zhou^2,4, Erin L. Ashbeck² and Dominick Sudano¹, ¹Division of Rheumatology, Department of Medicine, The University of Arizona, Tucson, AZ, ²University of Arizona Arthritis Center, Tucson, AZ, ³Department of Pharmacy, Practice and Science, College of Pharmacy, University of Arizona, TUCSON, AZ, ⁴College of Pharmacy, University of Arizona, Tucson, AZ
Background/Purpose: The 2016 Infectious Disease Society of America (IDSA) guidelines recommend serologic screening for coccidioidomycosis (Cocci) prior to initiation of biologic response modifiers (BRMs). Current…
Abstract Number: 2048 • 2018 ACR/ARHP Annual Meeting
In Vitro Proof-of-Concept of Pathobiology-Guided Therapy in Immune Mediated Inflammatory Arthritis
Morten Aagaard Nielsen¹, Bent Deleuran^2,3 and Tue Wenzel Kragstrup^2,3,4, ¹Of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Randers Regional Hospital, Randers, Denmark
Background/Purpose: Immune mediated inflammatory arthritis are very heterogeneous diseases including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and spondyloarthritis (SpA). The available biological and targeted synthetic…
Abstract Number: 2546 • 2018 ACR/ARHP Annual Meeting
The Association between Patient Reported Outcomes and Clinical Measures Among Rheumatoid Arthritis Patients: Analyses Using Phase 3 Clinical Trials of Upadacitinib
Vibeke Strand¹, Nemanja Damjanov², Craig Scoville³, Namita Tundia⁴, Heidi S. Camp⁴, Kun Chen⁴, Jessica Suboticki⁴ and Ronald van Vollenhoven⁵, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, ³Idaho Falls Arthritis Clinic, Idaho Falls, ID, ⁴AbbVie Inc., North Chicago, IL, ⁵Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
Background/Purpose: Patient-reported outcomes (PROs) in RA are important to evaluate total disease impact, although treatment decisions may often be guided by traditional physician-derived measures of…
Abstract Number: 546 • 2018 ACR/ARHP Annual Meeting
Baricitinib: Early Vs. Delayed Start in Patients with Rheumatoid Arthritis
Peter C. Taylor¹, Yoshiya Tanaka², Anabela Cardoso³, Jinglin Zhong⁴, Yun-Fei Chen³, Jennifer Lynn Workman³, Liliana del Carmen Morales⁵ and Michael Schiff⁶, ¹Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴IQVIA, Morrisville, NC, ⁵INStituto Reumatologica Strusberg, Cordoba, Argentina, ⁶University of Colorado, Greenwood Village, CO
Background/Purpose: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor approved for the treatment of moderately to severely active RA in adults in over 40 countries including…
Abstract Number: 1227 • 2018 ACR/ARHP Annual Meeting
Indicator Opportunistic Infections after Biological Treatment in Rheumatoid Arthritis, 10 Years Follow up in Clinical Practice
Leticia Leon^1,2, Marina Peñuelas³, Francisco Javier Candel³, Dalifer Freites Núñez⁴, Luis Rodriguez-Rodriguez⁵, Zulema Rosales Rosado⁶ and Lydia A Alcazar⁷, ¹Rheumatology Department, Hospital Clínical San Carlos, and IdISSC, Madrid, Spain, ²Health Sciences, Universidad Camilo Jose Cela, Madrid, Spain, ³Microbiology, Microbiology Department. Hospital Clínico San Carlos, Madrid, Spain., Madrid, Spain, ⁴Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁵Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁶Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ⁷Rheumatology Department and Heath Research Institute (IdISSC), Hospital Clinico San Carlos, Madrid, Spain
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) may be associated with opportunistic infections. Our purposes were to describe their incidence in Rheumatoid Arthritis (RA) taking bDMARDs,…
Abstract Number: 2185 • 2018 ACR/ARHP Annual Meeting
Direct Medical Costs for Medicare Patients with Rheumatoid Arthritis
Andrew Hresko¹, Zhi Zhang², Joshua Colls², Michael E Weinblatt², Nancy A. Shadick² and Daniel Solomon², ¹Tufts University School of Medicine, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) affects over 1 million Medicare enrollees. Despite the size of this population, costs for RA within Medicare remain poorly understood, especially…
Abstract Number: 2561 • 2018 ACR/ARHP Annual Meeting
Rapid and Sustained Improvements in Patient-Reported Signs and Symptoms with Ixekizumab in Biologic-Naive and TNF-Inadequate Responder Patients with Psoriatic Arthritis
Ana-Maria Orbai¹, Dafna D Gladman², Julie Birt³, Amanda M. Gellett³, Chen-Yen Lin³ and Tore Kvien⁴, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Toronto, Toronto, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Ixekizumab (IXE), a high-affinity mAb that selectively targets IL-17A, has shown improvements up to Week (Wk) 24 across several domains of PsA (including ACR20)…
Abstract Number: 560 • 2018 ACR/ARHP Annual Meeting
Impact of Formulary Copayment Change on Treatment Patterns in Rheumatoid Arthritis Patients on Etanercept
Hafiz Oko-osi¹, Machaon Bonafede², Mahdi Gharaibeh¹, Janna Manjelievskaia², Lorena Lopez-Gonzalez², David H. Collier¹ and Bradley S. Stolshek¹, ¹Amgen Inc., Thousand Oaks, CA, ²IBM Watson Health, Cambridge, MA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease that requires long-term treatment to improve or maintain disease activity. Tumor necrosis factor inhibitors (TNFi), a…
Abstract Number: 1251 • 2018 ACR/ARHP Annual Meeting
Guideline Adherence for Perioperative Use of Immunosuppressive Medications in Patients with Rheumatologic Disease
Grace Berlin, Carolyn Casey, Susan Kim and James Ross, Rheumatology, Lehigh Valley Health Network, Allentown, PA
Background/Purpose: In response to the lack of clear data to dictate recommendations for use of DMARDs and biologic therapy in the perioperative period, The American…

« Previous Page
1
…
4
5
6
7
8
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.